Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03475056 · ClinicalTrials.gov registry record · Phase 1
cAd3-Marburg Vaccine in Healthy Adults
A Phase 1 study of Marburg Virus Disease, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT03475056 is a Phase 1 study of Marburg Virus Disease that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03475056, a Phase 1 study of Marburg Virus Disease, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
RV 507 was a Phase I, open-label study to examine the safety, tolerability and immunogenicity of an investigational Marburg vaccine given by intramuscular (IM) injection to healthy adults. The study was a dose escalation of VRC-MARADC087-00-VP, a chimpanzee adenovirus serotype 3 (cAd3) vector vaccine, which encodes wild type (WT) glycoprotein (GP) from Marburgvirus.
Conditions Studied
Interventions
- BIOLOGICAL cAd3-Marburg vaccine
Study Locations (1)
Maryland
- WRAIR Clinical Trials Center, - Silver Spring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-10-09 |
| Est. Completion | 2019-12-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03475056
The ClinicalTrials.gov registry entry for NCT03475056 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Marburg Virus Disease appearing as the primary indexed condition, and to 1 intervention - of which cAd3-Marburg vaccine is the first listed.
NCT03475056 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT03475056 about?
NCT03475056 is a clinical study titled "cAd3-Marburg Vaccine in Healthy Adults". RV 507 was a Phase I, open-label study to examine the safety, tolerability and immunogenicity of an investigational Marburg vaccine given by intramuscular (IM) injection to healthy adults. The study was a dose escalation of VRC-MARADC087-00-VP, a chimpanzee adenovirus serotype 3 (cAd3) vector vaccin...
What is the current status of trial NCT03475056?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2018-10-09. Estimated completion is 2019-12-19.
What conditions does trial NCT03475056 study?
This clinical trial studies the following conditions: Marburg Virus Disease.
What interventions are being tested in trial NCT03475056?
The interventions under investigation include: cAd3-Marburg vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03475056?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03475056 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Marburg Virus Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.